Dexcom (DXCM) Net Cash Flow (2010 - 2026)

Dexcom (DXCM) has 17 years of Net Cash Flow data on file, last reported at $202.1 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 31.84% year-over-year to $202.1 million in Q1 2026; TTM through Mar 2026 was $195.9 million, a 256.18% increase from a year earlier, with the FY2025 full-year figure at $290.3 million, up 515.04% from the prior year.
• Net Cash Flow for Q1 2026 stood at $202.1 million, up from -$921.6 million in the prior quarter.
• Over the last five years, Net Cash Flow for DXCM reached as high as $677.7 million in Q3 2025 and fell as low as -$921.6 million in Q4 2025.
• Historically, Net Cash Flow has averaged $3.4 million across 5 years, with a median of -$3.9 million in 2024.
• Across the five-year window, Net Cash Flow surged 2331.78% in 2023 and tumbled 23530.77% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$62.6 million in 2022, then tumbled by 33.23% to -$83.4 million in 2023, then soared by 95.32% to -$3.9 million in 2024, then tumbled by 23530.77% to -$921.6 million in 2025, then surged by 121.93% to $202.1 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $202.1 million in Q1 2026, -$921.6 million in Q4 2025, and $677.7 million in Q3 2025.